BofA analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag.
Wall Street concerned about risk of recession and Morgan Stanley’s chief investment officer, Mike Wilson, urging tactical shift for investors.
Optimism among company CFO dropped in the first quarter as tariff risks and uncertainty began to cloud an outlook among business executives.
Everyday investors are continuing to buy the dip aggressively, even as Wall Street reacts to renewed trade tensions and recession fears.